Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Therapeutic effects of systemic administration of chaperone αB-crystallin associated with binding proinflammatory plasma proteins.

Rothbard JB, Kurnellas MP, Brownell S, Adams CM, Su L, Axtell RC, Chen R, Fathman CG, Robinson WH, Steinman L.

J Biol Chem. 2012 Mar 23;287(13):9708-21. doi: 10.1074/jbc.M111.337691.

2.

Hsp27 (HspB1) and alphaB-crystallin (HspB5) as therapeutic targets.

Arrigo AP, Simon S, Gibert B, Kretz-Remy C, Nivon M, Czekalla A, Guillet D, Moulin M, Diaz-Latoud C, Vicart P.

FEBS Lett. 2007 Jul 31;581(19):3665-74. Review.

3.

Cell biological roles of αB-crystallin.

Boelens WC.

Prog Biophys Mol Biol. 2014 Jul;115(1):3-10. doi: 10.1016/j.pbiomolbio.2014.02.005. Review.

PMID:
24576798
4.

Functional sequences in human alphaB crystallin.

Clark JI.

Biochim Biophys Acta. 2016 Jan;1860(1 Pt B):240-5. doi: 10.1016/j.bbagen.2015.08.014. Review.

PMID:
26341790
5.

HspB5/alphaB-crystallin: properties and current progress in neuropathy.

Hu Z, Li T.

Curr Neurovasc Res. 2008 May;5(2):143-52. Review.

PMID:
18473830
6.

Dynamical structure of αB-crystallin.

Hochberg GK, Benesch JL.

Prog Biophys Mol Biol. 2014 Jul;115(1):11-20. doi: 10.1016/j.pbiomolbio.2014.03.003. Review.

PMID:
24674783
7.

Mechanisms in the development of multiple sclerosis lesions: reconciling autoimmune and neurodegenerative factors.

van Noort JM, Baker D, Amor S.

CNS Neurol Disord Drug Targets. 2012 Aug;11(5):556-69. Review.

PMID:
22583440

Supplemental Content

Support Center